Dr. Alan Cochrane

Dr. Alan Cochrane

A novel compound that blocks HIV-1 replication inhibits the splicing regulatory function of SRSF10.NAR This study outlines the identification of a novel inhibitor (designated 1C8) of HIV-1 replication that functions through modulation of host splicing factor function, specifically SRSF10. While addition of 1C8 is found to severely impact HIV-1 RNA accumulation, the compound has very limited effects on host RNA processing. The anti-HIV activity of this compound suggests its use as a novel therapeutic to treat this infection.

Identification of Small Molecule Modulators of HIV-1 Tat and Rev Protein Accumulation.  Grosso et al describe the mechanism by which two cardiotonic steroids, digoxin and digitoxin, suppress replication of adenovirus. We demonstrate that these drugs do not affect virus entry or initiation of adenovirus gene expression, but alter the processing of viral RNA to negatively impact the production of other viral proteins and ultimately block virus DNA replication and assembly. The study is of note because it is a repurposing of a drug already approved for use in humans for an infection that currently has few treatment options.

Identification of Small Molecule Modulators of HIV-1 Tat and Rev Protein Accumulation. Retrovirology. Balachandran et al. identify three compounds (designated 791, 833, and 892) that suppress HIV-1 replication through effects on the expression of two essential viral regulatory factors, Tat and Rev. Data presented indicates that the compounds affect expression of these viral factors through changes in protein synthesis/stability. Despite the significant inhibition of HIV-1 replication/gene expression observed in the presence of these compounds, effects on host cell expression are limited. These observations highlight an alternative approach to the control of HIV-1.